Defensin (HBD-3)

HBD-3 has three extraordinary properties that set it apart: (1) It carries a +11 net charge at physiological pH — the highest among human beta-defensins — which drives powerful electrostatic attraction to bacterial membranes. (2) This high charge density makes it salt-insensitive, retaining full antimicrobial activity at 150 mM NaCl where HBD-1 and HBD-2 lose function. (3) Its antimicrobial mechanism doesn't require the canonical three disulfide bonds — even linearized (reduced) HBD-3 kills bacteria effectively. These combined properties produce MIC values of 0.5-1.0 μg/mL against MRSA, making it 50-100x more potent than HBD-2.

Most antimicrobial peptides, including HBD-1 and HBD-2, rely on electrostatic attraction to bacterial membranes. Physiological salt concentrations (150 mM NaCl) shield these charges, dramatically reducing antimicrobial activity. This means many defensins lose their killing power in real biological environments like wound fluid, blood, and airway surface liquid. HBD-3's salt-insensitivity means it functions effectively in the actual body environments where infections occur — a critical advantage for therapeutic development.

Bacterial biofilms are communities of bacteria encased in a protective extracellular matrix that makes them 100-1000x more resistant to conventional antibiotics. HBD-3 disrupts these biofilms at concentrations of 4-8 μg/mL against MRSA biofilms through its high cationic charge, which disrupts the anionic components of the biofilm matrix. Once the biofilm is disrupted, the released bacteria are susceptible to killing by both HBD-3 and conventional antibiotics — making HBD-3 an ideal partner for combination therapy with drugs that cannot penetrate biofilms alone.

HBD-3 kills bacteria through physical disruption of their cell membranes, which is fundamentally different from conventional antibiotics that target specific molecular pathways. For bacteria to become resistant, they would need to fundamentally alter their membrane lipid composition — a change so extreme it would likely compromise membrane function and viability. While some bacteria have evolved partial resistance mechanisms (surface charge modifications, protease secretion), the barrier to full resistance is far higher than for conventional antibiotics.

Most beta-defensins require their three disulfide bonds for proper folding and antimicrobial function. The discovery that HBD-3 retains full bactericidal activity even when these bonds are reduced (creating a linear peptide) was a surprising finding published in 2005 by Wu and colleagues. This means HBD-3's antimicrobial mechanism relies primarily on its high charge density rather than its 3D structure. Practically, this simplifies peptide synthesis for therapeutic development — linear peptides are much cheaper and easier to manufacture than disulfide-bonded ones.

Both are promising antimicrobial peptides for wound care, but with different strengths. LL-37 has advanced further clinically (Phase I/IIa and IIb trials completed), has stronger wound healing promotion through angiogenesis (FPRL1-mediated), and neutralizes endotoxin. HBD-3 is more potent against MRSA (0.5-1.0 vs ~10 μg/mL), more effective at disrupting biofilms, and has salt-insensitive activity. For chronic wounds colonized with antibiotic-resistant biofilm-forming bacteria, HBD-3 may be the superior antimicrobial agent, while LL-37 may be better for promoting wound closure. Combining both could provide optimal broad-spectrum antimicrobial and pro-healing coverage.